| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/28/2007 | US20070149539 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
| 06/28/2007 | US20070149536 2-[4-Bromomethyl)phenyl-3-phenylquinoxaline 1-2; selectively inhibits one or two of the serine/threonine protein kinase isoforms; antiproliferative |
| 06/28/2007 | US20070149498 Cancer therapy |
| 06/28/2007 | US20070149497 A tetrapyrollic photosensitizer compound having at least one pendant CH2CH2CON(CH2CON(CH2COOH)2)2 or N(CH2COOH)2 group, being a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide |
| 06/28/2007 | US20070149488 Tetracycline Derivatives and Methods of Use Thereof |
| 06/28/2007 | US20070149476 Combination Comprising Combretastatin and Anticancer Agents |
| 06/28/2007 | US20070149445 Aplidine for multiple myeloma treatment |
| 06/28/2007 | US20070148744 inhibitors of vacuolar-type H+-ATPase; antibiotic; (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16- [(1S,2R,3S)-3-[(2R,4R,5S,6R)-2,4-dihydroxy-6- isopropyl-5-methyl-2-tetrahydropyranyl]-2- hydroxy-1-methylbutyl]-8-hydroxy-3,15- dimethoxy-5,7,9,11-tetramethyl-1- oxacyclohexadeca-3,5,11,13-tetraen-2-one |
| 06/28/2007 | US20070148734 Hyaluronic acid mediated adenoviral transduction |
| 06/28/2007 | US20070148714 Clinical Parameters for Determining Hematologic Toxicity Prior to Radioimmunotherapy |
| 06/28/2007 | US20070148688 Novel human enzymes of the metalloprotease family |
| 06/28/2007 | US20070148263 comprises curcumin and an essential oil of turmeric |
| 06/28/2007 | US20070148261 Cancer treatment method |
| 06/28/2007 | US20070148256 Pharmacologic-functioning water and usage of the same |
| 06/28/2007 | US20070148254 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| 06/28/2007 | US20070148236 Pharmaceutical Compositions of Adsorbates of Amorphous Drug |
| 06/28/2007 | US20070148184 Survivin-derived peptides and use thereof |
| 06/28/2007 | US20070148178 Using beacizumab and antitumor agent as therapeutic treatment for mesothelioma |
| 06/28/2007 | US20070148177 Treatment with anti-vegf antibodies |
| 06/28/2007 | US20070148158 Rationally designed heparinases derived from heparinase II |
| 06/28/2007 | US20070148129 Therapeutic agents and uses therefor |
| 06/28/2007 | US20070148123 Substances and agents for positively influencing collagen |
| 06/28/2007 | DE20122735U1 Verwendung einer Zubereitung für Restenoseprophylaxe Use of a composition for prophylaxis of restenosis |
| 06/28/2007 | DE102006059063A1 Verwendung von BAY 59-3074 zur Herstellung von Medikamenten zur Therapie von Hirntumoren sowie Kombinationen von BAY 59-3074 The use of BAY 59-3074 for the preparation of medicaments for the therapy of brain tumors, as well as combinations of BAY 59-3074 |
| 06/28/2007 | DE102005062742A1 Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel Sulfoximine substituted pyrimidines, process for their preparation and their use as medicaments |
| 06/28/2007 | DE102005061840A1 Triazolderivate Triazole derivatives |
| 06/28/2007 | DE102005061655A1 Diazepinone Diazepinones |
| 06/28/2007 | DE102005060932A1 Pharmazeutische Zusammensetzung zur Behandlung von Tumoren und bestimmten Virenerkrankungen A pharmaceutical composition for treating tumors and certain virus diseases |
| 06/28/2007 | CA2669503A1 Compounds and methods for thiol-containing compound efflux and cancer treatment |
| 06/28/2007 | CA2634804A1 Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors |
| 06/28/2007 | CA2634468A1 Spiroketals |
| 06/28/2007 | CA2634291A1 Transcription factor decoy oligodeoxynucleotides having multiple cis elements |
| 06/28/2007 | CA2634212A1 Mif inhibitors |
| 06/28/2007 | CA2634116A1 Anti-ilt7 antibody |
| 06/28/2007 | CA2633776A1 Immuno-rna-constructs |
| 06/28/2007 | CA2633769A1 Crystalline form of vinflunine ditartrate |
| 06/28/2007 | CA2633756A1 Pharmaceutical antibody compositions with resistance to soluble cea |
| 06/28/2007 | CA2633742A1 Composition |
| 06/28/2007 | CA2633740A1 Aminopyrimidine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same |
| 06/28/2007 | CA2633713A1 Epha2 bite molecules and uses thereof |
| 06/28/2007 | CA2633346A1 Dna vaccine for cancer therapy |
| 06/28/2007 | CA2633131A1 Novel cancer-associated antigen |
| 06/28/2007 | CA2633101A1 Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer |
| 06/28/2007 | CA2632936A1 Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 06/28/2007 | CA2632929A1 Quinazoline derivatives, process for their preparation and their use as anti-cancer agents |
| 06/28/2007 | CA2632924A1 Chemical compounds |
| 06/28/2007 | CA2632881A1 Sulfoximine-substituted pyrimidines, their preparation and use as drugs |
| 06/28/2007 | CA2631868A1 Treatment of drug-resistant tumors |
| 06/28/2007 | CA2631764A1 Combination of zd6474 and pemetrexed |
| 06/28/2007 | CA2631721A1 Sulphonamidoaniline derivatives being janus kinases inhibitors |
| 06/28/2007 | CA2631676A1 Combination of azd2171 and pemetrexed |
| 06/28/2007 | CA2631653A1 Compounds having cytokine modulating properties |
| 06/28/2007 | CA2631069A1 Inhibitors of ccr9 activity |
| 06/27/2007 | EP1801208A1 Anti-a33 antibody |
| 06/27/2007 | EP1801193A1 Process for producing concentrate of unsaturated fatty acid |
| 06/27/2007 | EP1801123A2 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 06/27/2007 | EP1801115A1 Cyclic peptides and their use in treating advanced stage neuroblastoma |
| 06/27/2007 | EP1801112A1 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
| 06/27/2007 | EP1801106A2 New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| 06/27/2007 | EP1800697A2 Pharmaceutical compound, containing a stabilised mRNA which is optimised for translation in its coded areas |
| 06/27/2007 | EP1800695A1 Immuno-RNA-constructs |
| 06/27/2007 | EP1800693A1 Adjuvant therapy with the use of anti-glypican 3 antibody |
| 06/27/2007 | EP1800691A2 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| 06/27/2007 | EP1800684A1 Novel alkyl phospholipid derivatives and uses thereof |
| 06/27/2007 | EP1800676A1 Cancer chemotherapy |
| 06/27/2007 | EP1799866A2 Modulating mxa expression |
| 06/27/2007 | EP1799712A1 Cytotoxicity mediation of cells evidencing surface expression of mcsp |
| 06/27/2007 | EP1799707A1 Kunitz-type recombinant inhibitor. |
| 06/27/2007 | EP1799699A1 Analogs of 17-hydroxywortmannin as pi3k inhibitors |
| 06/27/2007 | EP1799698A1 Bioreductively-activated prodrugs |
| 06/27/2007 | EP1799691A1 Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors |
| 06/27/2007 | EP1799690A1 Thiazolyl-dihydro indazoles |
| 06/27/2007 | EP1799689A1 Furazano `3, 4-b ! pyrazynes and their use as anti-tumor agents |
| 06/27/2007 | EP1799686A1 Bioreductively-activated prodrugs |
| 06/27/2007 | EP1799685A2 Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
| 06/27/2007 | EP1799682A2 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
| 06/27/2007 | EP1799679A1 N,n'-dithenylurea derivatives used in the form of kinase inhibitors |
| 06/27/2007 | EP1799670A1 Benzoimidazole derivatives useful as antiproliferative agents |
| 06/27/2007 | EP1799669A1 Heterocyclic substituted bisarylurea derivatives as kinase inhibitors |
| 06/27/2007 | EP1799662A2 Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
| 06/27/2007 | EP1799659A1 Compounds for nonsense suppression, and methods for their use |
| 06/27/2007 | EP1799653A2 Novel heterocycles |
| 06/27/2007 | EP1799652A1 N-benzenesulfonyl substituted anilino-pyrimidine analogs |
| 06/27/2007 | EP1799651A2 Small molecule modulators of cytokine activity |
| 06/27/2007 | EP1799268A2 Magnetic particles for therapy and diagnosis |
| 06/27/2007 | EP1799267A2 Conjugates of hydroxyalkyl starch and a protein |
| 06/27/2007 | EP1799250A2 Use of igfbp-2 in senescence diseases and for the maintenance of organ functions |
| 06/27/2007 | EP1799227A2 Therapeutic agents targeting the nc ca-atp channel and methods of use thereof |
| 06/27/2007 | EP1799226A1 Use of midostaurin for treating gastrointestinal stromal tumors |
| 06/27/2007 | EP1799218A1 Hcv inhibiting bi-cyclic pyrimidines |
| 06/27/2007 | EP1799215A2 Chemokine-binding heterocyclic compound salts, and methods of use thereof |
| 06/27/2007 | EP1799213A2 Novel curcumin analogues and uses thereof |
| 06/27/2007 | EP1799201A1 4-hydroxy tamoxifen gel formulations |
| 06/27/2007 | EP1799053A2 Peptide mixture from peptides having a molecular weight of from 1000 to 5000 dalton |
| 06/27/2007 | EP1636212B1 Cycloalkylsulfanyl substituted benzo¬b|thiophenes as therapeutic agents |
| 06/27/2007 | EP1590352B1 4-AMINOTHIENO [2,3-d] PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS |
| 06/27/2007 | EP1531812B1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis |
| 06/27/2007 | EP1485376B1 Compositions useful as inhibitors of protein kinases |
| 06/27/2007 | EP1368312B1 Benzo[f]isoindole derivatives with affinity to the ep4 receptor |
| 06/27/2007 | EP1355936B1 Polymer conjugates of neublastin and methods of using same |